We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
Read MoreHide Full Article
Shares of Matinas BioPharma (MTNB - Free Report) were up 23.2% on Monday after it announced that it has signed a research collaboration agreement with BioNTech (BNTX - Free Report) .
Per the collaboration agreement, Matinas BioPharma will work exclusively with BioNTech to evaluate a novel delivery technology for mRNA-based vaccines leveraging the Matinas BioPharma’s proprietary lipid nanocrystal (LNC) platform technology. As part of the deal, both BNTX and MTNB will also work to make the oral novel mRNA-based vaccines.
Both Matinas BioPharma and BioNTech will work closely with each other on formulation, optimization and in vitro testing.
Per the terms of the agreement, Matinas BioPharma will receive an undisclosed fee as upfront payment and will also be eligible to receive additional research funding from BioNTech. The press release did not disclose any specific terms of the deal. Both companies also started discussions on licensing agreements for MTNB’s LNC platform.
Shares of Matinas BioPharma have declined 5.2% so far this year compared with the industry’s 15% decrease.
Image Source: Zacks Investment Research
Currently with no approved product in its portfolio, Matinas BioPharma is highly dependent on its pipeline development for growth. Using its LNC technology, MTNB developed two potent anti-infective small molecules, namely MAT2203 and MAT2501. Funds from the above partnership will help MTNB support its pipeline development.
MAT2203 is Matinas BioPharma’s lead drug and is the oral formulation of amphotericin B, a well-known and highly effective antifungal drug. This oral formulation is currently being evaluated in a phase II study in multiple cohorts for the treatment of cryptococcal meningitis. Matinas BioPharma plans to meet with the FDA officials in second-quarter 2022 to discuss the requirements of a regulatory filing for the candidate.
MTNB’s second candidate is MTA2501 (oral amikacin), currently being evaluated in an early-stage study for the treatment of non-tuberculous mycobacterial (NTM), a severe lung infection. Data from this study is expected in second-quarter 2022.
Matinas BioPharma presently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Angion Biomedica and Collegium Pharmaceutical (COLL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.52 to $1.92 in the past 60 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 60 days.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark in one, the average surprise being 47.5%.
Collegium Pharmaceutical’s earnings per share estimates for 2022 have increased from $3.79 to $5.59 in the past 60 days. The same for 2023 has increased from $4.79 to $7.44 in the past 60 days. Shares of COLL have risen 5.3% year to date.
Earnings of Collegium Pharmaceutical missed estimates in three of the last four quarters and beat the mark on one occasion, the negative surprise being 57.6%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
Shares of Matinas BioPharma (MTNB - Free Report) were up 23.2% on Monday after it announced that it has signed a research collaboration agreement with BioNTech (BNTX - Free Report) .
Per the collaboration agreement, Matinas BioPharma will work exclusively with BioNTech to evaluate a novel delivery technology for mRNA-based vaccines leveraging the Matinas BioPharma’s proprietary lipid nanocrystal (LNC) platform technology. As part of the deal, both BNTX and MTNB will also work to make the oral novel mRNA-based vaccines.
Both Matinas BioPharma and BioNTech will work closely with each other on formulation, optimization and in vitro testing.
Per the terms of the agreement, Matinas BioPharma will receive an undisclosed fee as upfront payment and will also be eligible to receive additional research funding from BioNTech. The press release did not disclose any specific terms of the deal. Both companies also started discussions on licensing agreements for MTNB’s LNC platform.
Shares of Matinas BioPharma have declined 5.2% so far this year compared with the industry’s 15% decrease.
Image Source: Zacks Investment Research
Currently with no approved product in its portfolio, Matinas BioPharma is highly dependent on its pipeline development for growth. Using its LNC technology, MTNB developed two potent anti-infective small molecules, namely MAT2203 and MAT2501. Funds from the above partnership will help MTNB support its pipeline development.
MAT2203 is Matinas BioPharma’s lead drug and is the oral formulation of amphotericin B, a well-known and highly effective antifungal drug. This oral formulation is currently being evaluated in a phase II study in multiple cohorts for the treatment of cryptococcal meningitis. Matinas BioPharma plans to meet with the FDA officials in second-quarter 2022 to discuss the requirements of a regulatory filing for the candidate.
MTNB’s second candidate is MTA2501 (oral amikacin), currently being evaluated in an early-stage study for the treatment of non-tuberculous mycobacterial (NTM), a severe lung infection. Data from this study is expected in second-quarter 2022.
Matinas Biopharma Holdings, Inc. Price
Matinas Biopharma Holdings, Inc. price | Matinas Biopharma Holdings, Inc. Quote
Zacks Rank & Other Key Picks
Matinas BioPharma presently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the overall healthcare sector are Angion Biomedica and Collegium Pharmaceutical (COLL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.52 to $1.92 in the past 60 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 60 days.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark in one, the average surprise being 47.5%.
Collegium Pharmaceutical’s earnings per share estimates for 2022 have increased from $3.79 to $5.59 in the past 60 days. The same for 2023 has increased from $4.79 to $7.44 in the past 60 days. Shares of COLL have risen 5.3% year to date.
Earnings of Collegium Pharmaceutical missed estimates in three of the last four quarters and beat the mark on one occasion, the negative surprise being 57.6%, on average.